Topic: Private Equity Firm
Bayer's sale of its animal health unit is attracting interest from a wide variety of players, including private equity firms and even rivals, a new report reveals.
When Mylan said last month that it would consider a sale, analysts were skeptical the company could find an interested buyer.
Nasdaq-listed Sinovac accused OrbiMed, 1Globe Capital and a buyer consortium led by Sinobioway of conspiring a hostile takeover.
Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."
Just five months after Allergan’s CEO said the company wouldn’t break up, it’s reportedly weighing options for its women’s health unit.
China issued expansive drug policy change guidelines, the FDA rejected Mylan and Biocon's Neulasta biosim, C-Bridge hired ex-GSK exec Hussain.
Last week, an activist investor held out on the buyout offer for Stada—and it worked.
QuintilesIMS is weighing a sale of its contract sales business that could be worth up to $1 billion, according to Reuters.
Buyout target Stada is rolling out cost-cutting measures and new guidance in an attempt to bring in larger bids.
The race to snatch up generics maker Stada is heating up—and fast—with multiple players reportedly preparing to jump in, including Chinese drugmakers and, improbably, U.S.-based Merck.